Related Experiment Video

Updated: Mar 19, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

12.1K

Efficacy and safety of itraconazole use in infants

Shuang Chen1, Kai-Yi Sun1, Xiao-Wei Feng1

  • 1Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, 610041, China.

World Journal of Pediatrics : WJP
|June 12, 2016
PubMed
Abstract

Insights

Itraconazole is a safe and effective antifungal medication for treating superficial and systemic fungal infections in infants. Dosing recommendations vary by infection type, with established safety profiles similar to adults.

Area of Science:

  • Pediatric Mycology
  • Pharmacotherapy
  • Infectious Diseases

Background:

  • Itraconazole is widely used for fungal infections, particularly invasive types in neonates and infants.
  • Evidence-based guidelines for its pediatric use are essential for effective treatment.

Purpose of the Study:

  • To outline the administration of itraconazole in infants.
  • To develop evidence-based pharmacotherapy for infantile fungal infections.

Main Methods:

  • Comprehensive literature search across multiple databases (Ovid EMBASE, PubMed, Web of Science, CNKI, Google Scholar).
  • Keywords included 'pediatric,' 'infant,' 'neonate,' 'fungal infection,' and 'itraconazole.'
  • Synthesis of findings from 45 relevant articles combined with clinical experience.

Main Results:

  • 13 articles focused on superficial fungal infections (e.g., tinea capitis, mucosal infections).
  • 32 articles addressed systemic fungal infections (e.g., candidiasis, aspergillosis, histoplasmosis).
  • Itraconazole demonstrated efficacy across a range of pediatric fungal infections.

Conclusions:

  • Itraconazole is safe and effective for superficial fungal infections at 5 mg/kg/day and systemic infections at 10 mg/kg/day in infants.
  • The drug is cost-effective with good compliance for infantile fungal infections.
  • Adverse event profiles in infants mirror those observed in adult and pediatric populations.
Keywords:
infantitraconazoleprophylaxissuperficial fungal infectionssystemic fungal infections

More Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.8K
Identification of Small Molecule-binding Proteins in a Native Cellular Environment by Live-cell Photoaffinity Labeling10:49

Identification of Small Molecule-binding Proteins in a Native Cellular Environment by Live-cell Photoaffinity Labeling

Published on: September 20, 2016

13.4K

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
698
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
360
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
652
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.2K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
313
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
653